Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br B Conditioned Media Collection B Endothelial Cell Invasio

    2020-03-17


    B Conditioned Media Collection B Endothelial Cell Invasion Assay B Tube Formation Assay
    B Rat Aortic Ring Assay
    B Chicken Chorioallantoic Membrane (CAM) Assay B In Vivo Angiogenesis Study
    B Preparation of Cytosolic and Nuclear Extracts B Immunofluorescence Staining
    d QUANTIFICATION AND STATISTICAL ANALYSIS d DATA AND SOFTWARE AVAILABILITY
    SUPPLEMENTAL INFORMATION
    Supplemental Information can be found online at https://doi.org/10.1016/j.
    ACKNOWLEDGMENTS r> This work was supported by the National Heart, Lung, and Blood Institute of the NIH under award numbers K99HL138272 and R00HL138272 to F.C. This work has been also funded in whole or in part with Federal funds from the Fred-erick National Laboratory for Cancer Research, NIH, under contract HHSN261200800001E. This research was supported (in part) by the Intramural Research Program of NIH, Frederick National Lab, Center for Cancer Research. The content of this SC 560 publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. C.E. is the Sondra J and Stephen R Har-dis Endowed Chair in Cancer Genomic Medicine at the Cleveland Clinic, and an ACS Clinical Research Professor.
    AUTHOR CONTRIBUTIONS
    DECLARATION OF INTERESTS
    F.C. and C.E. have a pending patent application related to this study. The other authors declare no conflict of interest.
    REFERENCES
    Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70.
    Cella, D., Wang, M., Wagner, L., and Miller, K. (2011). Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res. Treat 130, 855–861.
    Coordinators, N.R. (2017). Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 45, D12–D17.
    Earl, H.M., Hiller, L., Dunn, J.A., Blenkinsop, C., Grybowicz, L., Vallier, A.L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., et al. (2015). Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluoro-uracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 16, 656–666.
    Fang, J., Cai, C., Wang, Q., Lin, P., Zhao, Z., and Cheng, F. (2017a). Systems pharmacology-based discovery of natural products for precision oncology through targeting cancer mutated genes. CPT Pharmacometrics Syst. Pharmacol. 6, 177–187.
    Please cite sympathetic system article in press as: Huang et al., A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling, Cell Chemical Biology (2019), https://doi.org/10.1016/j.chembiol.2019.05.004
    Antiangiogenic strategies in breast cancer management. Crit. Rev. Oncol.
    GTEx Consortium (2015). The Genotype-Tissue Expression (GTEx) pilot anal-ysis: multitissue gene regulation in humans. Science 348, 648–660.
    Linderholm, B.K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtio, J., and Lewensohn, R. (2009). Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol. 20, 1639–1646.
    von Minckwitz, G., Puglisi, F., Cortes, J., Vrdoljak, E., Marschner, N., Zielinski, C., Villanueva, C., Romieu, G., Lang, I., Ciruelos, E., et al. (2014b). Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 15, 1269–1278. SC 560